AUS
NZ
UK
CA
USA
IND
Growthpoint Properties Australia (ASX:GOZ) has requested the Quotation of 181,456 fully paid ordinary stapled securities on the ASX, resulting from the conversion of deferred short-term incentive (STI) performance rights under its FY24 and FY25 employee incentive schemes. These securities were issued on 30 June 2026 without any cash payment from the holders, in line with the terms of the deferred STI plans. Included in this conversion were 48,356 performance rights held by key management personnel, specifically CEO Ross Lees, via an associated entity. This issuance increases Growthpoint's total quoted stapled securities to 754,608,746, with various performance rights still outstanding across multiple unquoted classes.
Key Points
- Company: Growthpoint Properties Australia (ASX:GOZ)
- Conversion of 181,456 GOZAC STI performance rights into fully paid ordinary stapled securities (GOZ) on 30 June 2026
- Rights vested under FY24 (Tranche 2) and FY25 (Tranche 1) deferred STI employee incentive plans, with no cash consideration required
- VWAP reference prices used for the plans were $2.18 and $2.39 per stapled security respectively
- Key management personnel involvement: Ross Lees converted 48,356 performance rights through associated entity Elgin1906 Pty Ltd ATF Lees Family A/C
- Total quoted GOZ stapled securities after this issue: 754,608,746
- Outstanding unquoted performance rights include 4,009,399 LTI rights (GOZAA), 124,482 (GOZAJ), and 121,065 STI rights (GOZAC)
Issuance of 181,456 GOZ Stapled Securities Following 30 June 2026 Performance Rights Vesting
On 1 July 2026, Growthpoint Properties Australia filed an Appendix 2A with the ASX applying for the quotation of 181,456 fully paid ordinary stapled securities. These securities were issued on 30 June 2026 following the conversion of GOZAC performance rights classified as short-term incentive (STI) rights under the company's employee incentive program.
This conversion transitioned rights from the unquoted GOZAC class into the existing quoted GOZ class, representing Growthpoint’s fully paid ordinary stapled securities. From the issue date, these new securities carry equal rights to distributions, voting, and other entitlements as existing GOZ securities.
Conversion Driven by FY24 Tranche 2 and FY25 Tranche 1 Deferred STI Plans
The vested and converted performance rights originated from two tranches of Growthpoint’s deferred STI incentive plans. The FY24 Tranche 2 plan applied a ten-trading-day volume weighted average price (VWAP) of $2.18 per stapled security at grant, while the FY25 Tranche 1 plan used a VWAP of $2.39. These VWAPs determined the number of rights granted rather than a conversion price.
Recipients did not pay any cash consideration upon vesting, consistent with deferred equity remuneration structures where value is inherent in the rights themselves. This approach aligns management incentives with long-term securityholder interests and is common among ASX-listed real estate investment trusts and diversified property groups.
Key Management Personnel Ross Lees Converts 48,356 Performance Rights via Associated Entity
The update confirms that key management personnel participated in the conversion. Ross Lees, CEO and a key management personnel member, converted 48,356 GOZAC STI performance rights held through the associated entity Elgin1906 Pty Ltd ATF Lees Family A/C.
Disclosure of key management personnel involvement is mandatory in Appendix 2A filings when such personnel or their associates hold converting securities. The remaining 133,100 converted rights belong to other plan participants, though their identities were not disclosed.
Growthpoint’s Quoted Stapled Securities Total 754,608,746 After Issuance
Following the quotation of these 181,456 stapled securities, Growthpoint’s total quoted securities increased to 754,608,746 GOZ units. This figure is generated by ASX systems during the Appendix 2A process and may not fully reflect current issued capital if other filings are being processed concurrently.
The newly issued securities represent a minimal dilution to existing holders and reflect ongoing equity-based remuneration activity. Growthpoint has not indicated any changes to its distribution policy, earnings guidance, or strategic direction related to this issuance.
Outstanding Performance Rights Across GOZAA, GOZAJ, and GOZAC Classes
Post-conversion, Growthpoint’s unquoted register still holds a significant number of performance rights: 4,009,399 long-term incentive (LTI) rights in the GOZAA class, 124,482 rights in GOZAJ, and 121,065 STI rights remaining in GOZAC after this conversion.
These outstanding rights indicate potential future conversions as additional tranches vest. Investors monitoring dilution risk or remuneration structures should particularly observe the GOZAA LTI rights, which comprise the largest unquoted class. Vesting schedules for remaining rights were not disclosed.
No Cash Proceeds Raised from This Securities Issuance
Since the performance rights were granted as deferred compensation under the FY24 and FY25 STI plans, Growthpoint did not receive any cash inflow from their conversion into stapled securities. The consideration per security was zero, consistent with employee equity plan vesting events.
This distinguishes the transaction from capital raises or placements and means there is no direct impact on Growthpoint’s balance sheet liquidity or its capacity to fund acquisitions, capital expenditure, or debt repayments. The event primarily affects remuneration transparency and the accuracy of securities on issue, important for analysts and institutional investors assessing governance and equity structure.
Role of Deferred STI Plans Within Growthpoint’s Remuneration Framework
Deferred short-term incentive plans reward employees and executives for performance in a given financial year but delay equity delivery over a subsequent period. This deferral acts as a retention tool and aligns interests with securityholders, as the value depends on Growthpoint’s security price at grant and throughout the holding period.
Growthpoint’s FY24 and FY25 STI plans each included multiple tranches, with FY25 Tranche 1 and FY24 Tranche 2 vesting simultaneously on 30 June 2026. Such staggered vesting is typical among Australian listed companies, allowing multiple prior-year tranches to vest in a single year. No forward vesting schedule was provided.
Implications for GOZ Securityholders of Performance Rights Conversions
For existing Growthpoint securityholders, the periodic conversion of performance rights into stapled securities is a routine but important event. While this issuance of 181,456 securities against a base exceeding 754 million is not materially dilutive, cumulative vesting across GOZAA, GOZAJ, and GOZAC classes over time could meaningfully increase the securities count.
The immediate impact on share price was not evident from public information. Investors focused on property portfolio performance, distribution yield, and net tangible asset backing are likely to view this as a routine corporate matter rather than an indicator of strategic or financial change. Future Appendix 2A filings and financial or distribution announcements will be key milestones to monitor.
About Growthpoint Properties Australia and Its ASX Listing
Growthpoint Properties Australia is an ASX-listed stapled security group trading under ticker GOZ, comprising Growthpoint Properties Australia Trust (ARSN 120 121 002) and Growthpoint Properties Australia Limited (ABN 33 124 093 901). It is an internally managed real estate investment trust focused on Australian office and industrial property sectors. Each GOZ unit represents combined interests in both entities, with distributions derived from both.
The use of stapled securities in employee incentive plans aligns recipients’ economic exposure with the underlying property portfolio. Following this conversion, the total quoted stapled securities stand at 754,608,746. The company’s capital structure remains broadly unchanged regarding market capitalization, which depends on the prevailing GOZ security price.
